Mesoblast Ltd.
(NASDAQ: MESO)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $6.80 | Change: +0.35 | %Change: +5.50% | Volume: 83,234 |
Open: | $ 6.54 | Volume: | 83,234 | |
---|---|---|---|---|
High: | $ 6.87 | Yield(%) | 0.00 | |
Low: | $ 6.50 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 736.10M | |
EPS ($) | -1.06 | Shares Out: | 114.12M |
% Price Change (last 4 weeks): | -14.91 |
---|---|
% Price Change (last 13 weeks): | -2.12 |
% Price Change (last 26 weeks): | 198.61 |
% Price Change (last 52 weeks): | -14.34 |
% Price Change (year to date): | 193.18 |
Return on Equity (%): | -16.40 |
---|---|
Return on Assets (%): | -11.54 |
Return on Invested Capital (%): | -14.45 |
Gross Profit Margin (%): | -269.72 |
---|---|
Net Profit Margin (%): | -1091.71 |
Operating Profit Margin (%): | -970.47 |
|
|
50-day Moving Average: | $7.18 |
---|---|
200-day Moving Average: | $3.77 |
Avg. Daily Vol. (last 50 days): | 215,001 |
Avg. Daily Vol. (last 200 days): | 818,217 |
52-wk high: | $10.24 |
52-wk low: | $1.61 |
Bid: | $6.81 |
Ask: | $6.97 |
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
|
Mesoblast Ltd.
55 Collins Street Level 38 Melbourne VI 3000 Phone: 61.3.9639.6036 Fax: 61.3.9639.6030 http://www.mesoblast.com |
Earnings (1year) ($): | -1.06 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 5.85 |
Cash Flow ($): | -0.91 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 76.77 |
Price/Book (x): | 1.26 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 1.95 |
---|---|
Current Ratio (x): | 1.95 |
LT Debt/Equity (x): | 21.22 |
Total Debt/Equity (x): | 23.21 |